Literature DB >> 20160897

Studies toward the duocarmycin prodrugs for the antibody prodrug therapy approach.

Lian-Sheng Li1, Subhash C Sinha.   

Abstract

A tricyclic precursor for the synthesis of the prodrugs of pro-1,2,9,9a-tetrahydrocyclopropa[c]benz-[e]indole-4-one tetramethoxyindolecarboxamide (CBI-TMI) was prepared using the ring-closing metathesis approach. The tricyclic intermediate was converted to an advanced precursor of a CBI-TMI prodrug equipped with a linker presumably suitable for activation using the aldolase catalytic antibody 38C2. An attempted 38C2-catalyzed two-step activation of the hydroxy-pro-CBI intermediate involving retro-aldol and the β-elimination reactions was also examined.

Entities:  

Year:  2009        PMID: 20160897      PMCID: PMC2768327          DOI: 10.1016/j.tetlet.2009.03.205

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  13 in total

1.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

3.  Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.

Authors:  Subhash C Sinha; Lian-Sheng Li; Gregory P Miller; Shantanu Dutta; Christoph Rader; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

4.  Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp.

Authors:  M Ichimura; T Ogawa; K Takahashi; E Kobayashi; I Kawamoto; T Yasuzawa; I Takahashi; H Nakano
Journal:  J Antibiot (Tokyo)       Date:  1990-08       Impact factor: 2.649

Review 5.  Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies.

Authors:  T Wójcik; K Kieć-Kononowicz
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.

Authors:  Sunny Abraham; Fang Guo; Lian-Sheng Li; Christoph Rader; Cheng Liu; Carlos F Barbas; Richard A Lerner; Subhash C Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

7.  Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double-stranded DNA.

Authors:  M A Gieseg; J Matejovic; W A Denny
Journal:  Anticancer Drug Des       Date:  1999-02

Review 8.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Duocarmycin-based prodrugs for cancer prodrug monotherapy.

Authors:  Lutz F Tietze; Heiko J Schuster; Kianga Schmuck; Ingrid Schuberth; Frauke Alves
Journal:  Bioorg Med Chem       Date:  2008-05-07       Impact factor: 3.641

10.  Total synthesis and evaluation of iso-duocarmycin SA and iso-yatakemycin.

Authors:  Karen S MacMillan; Trinh Nguyen; Trihn Nguyen; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2009-01-28       Impact factor: 15.419

View more
  6 in total

1.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

2.  Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

3.  The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.

Authors:  Krishna Mohan Bajjuri; Yuan Liu; Cheng Liu; Subhash C Sinha
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

4.  A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Scott J Weir; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2012-06-12       Impact factor: 7.446

5.  Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.

Authors:  James P Lajiness; William M Robertson; Irene Dunwiddie; Melinda A Broward; George A Vielhauer; Scott J Weir; Dale L Boger
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

6.  A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.

Authors:  Amanda L Wolfe; Katharine K Duncan; James P Lajiness; Kaicheng Zhu; Adam S Duerfeldt; Dale L Boger
Journal:  J Med Chem       Date:  2013-08-29       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.